Home » Featured, NHS Research News

Revolutionary Stem Cell Stroke Trial Continues

No Comment

The first round of using stem cells to treat stroke victims has proved successful, meaning the trial has been given the go-ahead to continue.

UK company, ReNureon, is carrying out neural stem cell therapy, known as ReN001, in an attempt to aid patients who’ve been left severely damaged by a cerebrovascular accident (stroke).  This is the first trial in the world to use stem cells in order to reverse various paralysis and damage, and so far three patients have been treated.

An independent board has been monitoring the trial that has taken place with three patients over a nine month period.  A low dose has been administered with patients monitored at three monthly intervals.  The results are proving positive, and the board has given consent for the doses to now be raised.

The trial, known as PISCES (Pilot Investigation of Stem Cells in Stroke), is being headed by Professor Keith Muir from Glasgow’s Centre for Stroke Research.  It’s hoped that this pioneering treatment will prove a real boost for patients suffering disability caused by ischemic stroke.

12 patients are being included in the trial.  The next three will commence treatment at the higher dose before the end of 2011, and the following patients will be treated in 2012.  Each will be monitored for a period of no less than two years after treatment, with longer-term procedures also in place as follow-ups.

The trial is being carried out in Scotland in association with the Greater Glasgow Clyde NHS Trust, Southern General Hospital and the Institute of Neurological Sciences.  Professor Muir will present the findings of the study so far at the UK Stroke Forum Conference held in Glasgow at the end of the year.

Share and Enjoy:
  • Print
  • Digg
  • StumbleUpon
  • del.icio.us
  • Facebook
  • Yahoo! Buzz
  • Twitter
  • Google Bookmarks
  • LinkedIn